GSK3B and diabetes mellitus: Catalpol ameliorated hepatic insulin resistance and reduced diabetes-associated hepatic injury and steatosis in HFD/STZ induced diabetic mice which was mediated through activation of 5′ adenosine monophosphate-activated protein kinase (AMPK), increased glycogen synthase kinase 3 beta (GSK3β) phosphorylation, reduced glycogen synthase phosphorylation, stimulation of hepatic glycogen synthesis, and inhibition of hepatic gluconeogenesis [20].